title: Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
authors.forename: Ehud
authors.initials: E
authors.lastname: Even-Or
authors.forename: Rachel
authors.initials: R
authors.lastname: Becker-Cohen
authors.forename: Hagit
authors.initials: H
authors.lastname: Miskin
mesh_terms: D000293:Adolescent; D001565:Benzoates / Q000008:administration & dosage*; D002648:Child; D000077588:Deferasirox; D005198:Fanconi Syndrome / Q000628:therapy* / Q000652:urine; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D007668:Kidney / Q000378:metabolism; D008297:Male; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox